Nutcracker Therapeutics Announces Two Preclinical Data Presentations for Lead mRNA Candidate, NTX-250, at the 2023 AACR Annual Meeting
3-28-2023
EMERYVILLE, Calif., March 27, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present two posters outlining new preclinical data for its lead therapeutic candidate, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Fla., from April 14-19.
Nutcracker’s presentations describe how the three RNA-encoded protein components of NTX-250 (HPV E6/E7, IL-12, and LIGHT) work synergistically to drive enhanced immune responses and tumor clearance in murine models of HPV-driven tumors. In humans, some types of HPV infection can lead to the development of cervical intraepithelial neoplasia, which will be the lead indication for NTX-250, and is a precursor to cervical cancer. Nutcracker will also present preclinical data on how specific trafficking domains can lead to enhanced immune responses for RNA-based therapies.
Poster Presentations at the 2023 AACR Annual Meeting
Title: Modification of mRNA-encoded HPV16 antigens to include endolysosomal trafficking domains drives cross-presentation and results in superior in vivo and ex vivo antigen-specific responses
Abstract Number: 690
Session Title: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies
Session Date and Time: April 16, 2023, 1:30 p.m. - 5:00 p.m. ET
Location: Orange County Convention Center, Poster Section 24
Presenting Author: Ole Audun W. Haabeth
Title: Local delivery of mRNA immunotherapy encoding HPV16 antigen, IL-12, and LIGHT/TNFSF14 results in superior immunogenicity and tumor clearance in a murine model of HPV16-driven cancer
Abstract Number: 5163
Session Title: Modifiers of the Tumor Microenvironment
Session Date and Time: April 18, 2023, 1:30 p.m. - 5:00 p.m. ET
Location: Orange County Convention Center, Poster Section 24
Presenting Author: Ole Audun W. Haabeth
In addition to the above, the research groups of Dr. Lawrence Fong and Dr. David Oh at the University of California, San Francisco will present data from a study conducted in collaboration with Nutcracker Therapeutics. The details are as follows:
Title: Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients
Abstract Number: LB346
Session Title: TBD
Session Date and Time: TBD
Location: Orange County Convention Center, Poster Section TBD
Presenting Author: Elena Montauti
Full abstracts are available on the AACR Online Program Planner. More information about the conference can be found on AACR’s website.
About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker’s technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.
For more information, visit www.nutcrackerx.com.
Media Contact:
Geir Falck-Pedersen
HDMZ
Nutcrackerpr@hdmz.com
(312) 506-5244
Previous Article
